CURE

Pelareorep Receives FDA Fast Track Status for KRAS-Mutant Colorectal Cancer

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat populationCompany ...
Targeted Oncology

Pelareorep Earns FDA Fast Track for Second-Line KRAS-Mutant Metastatic CRC

The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...